Cordis receives CE mark for Renlane to treat resistant hypertension

theflyonthewall.com

Cordis, part of the Johnson & Johnson Family of Companies, announced that it has received European CE Mark for its Renlane Renal Denervation System for the treatment of patients with resistant hypertension and has completed the first successful cases in Europe. The Renlane System consists of a unique, helical shaped, irrigated, multi-electrode ablation catheter with a multi-channel radiofrequency ablation system. The first successful cases were performed by Hannes Reuter, M.D., at the University of Cologne Hospital in Germany. The treated patients were diagnosed with resistant hypertension and had systolic blood pressures greater than or equal to 160 mm Hg, despite undergoing traditional drug therapy with three or more anti-hypertensive medications. All procedures were performed successfully and patients were discharged after one day.

Rates

View Comments (0)